companyHealthcare / Assisted Reproductive TechnologyAustralia

Virtus Health

Australian-headquartered global provider of assisted reproductive technology (ART) and fertility services

Virtus Health is a Sydney-based healthcare company specialising in assisted reproductive technology (ART), specialist pathology, and day hospital services. Founded in 2010 and listed on the ASX in June 2013, it was taken private in August 2022 following an acquisition by Australian private equity firm BGH Capital for approximately $518 million.

The company operates across Australia, Singapore, Ireland, the UK, and Denmark, making it one of the top five providers of assisted reproductive services in the world. Its Australian operations span seven specialist day hospitals across Queensland, NSW, Victoria, and Tasmania, offering services in fertility and IVF, gynaecology, plastic and cosmetic surgery, dentistry, ophthalmology, urology, orthopaedics, and general surgery.

Virtus Health's brand portfolio includes Queensland Fertility Group, IVFAustralia, Melbourne IVF, TasIVF, Sims IVF (Ireland), Rotunda IVF, Aagaard Fertility Clinic (Denmark), and Virtus Fertility Centre (Singapore). Its diagnostics division, Virtus Diagnostics, was established in 2015 and provides general pathology as well as specialist fertility and genetic testing.

Growth has been driven substantially through acquisition, with notable purchases including Sims IVF, Rotunda IVF, TasIVF, and IDS Pathology, among others. As one of the largest integrated fertility practices globally, Virtus Health is a significant player in the reproductive medicine and women's health sector.

Ideas that could help Virtus Health

TEX44/CPT1B Genetic Panel for Asthenozoospermia Diagnosis
A targeted next-generation sequencing panel that screens male infertility patients for biallelic TEX44 and CPT1B variants, giving clinicians a molecular diagnosis for a previously unexplained cause of sperm motility failure.
Why it helps: Virtus operates one of the largest fertility clinic networks in Australia and Southeast Asia; a validated TEX44 diagnostic panel could differentiate their genetic workup for idiopathic male infertility patients.